Abstract
Gentamicin sulfate or neomycin sulfate injected intraperitoneally into 24- to 27-g mice at a dose of 6.2 mg per mouse elicited botulism-like responses in less than 30 min, but a dose of 3.1 mg per mouse had no observable effect. The normally nontoxic 3.1-mg aminoglycoside dose aggravated the illness induced by an earlier injection of Clostridium botulinum type A or B toxin; it was usually lethal in 2 to 20 min if the preexisting illness was moderate to severe and worsened the condition of mice for about 30 min if the preexisting botulism was mild. The aminoglycoside had no effect when given shortly after the botulinum toxin was injected intraperitoneally; the sensitized state followed a latent period. It rapidly produced botulism-like effects when given to mice which had responded to a mixture of botulinum toxin and another mouse toxic agent with an illness that did not include signs of botulism. An unexpected illness devoid of botulism-like effects was encountered during intestinal colonization of mice by C. botulinum. The appearance of botulism-like signs soon after 3.1 mg of gentamicin sulfate was injected supported other suggestions that this illness included botulism that was masked by the effects of a second cause.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Arnon S. S. Infant botulism. Annu Rev Med. 1980;31:541–560. doi: 10.1146/annurev.me.31.020180.002545. [DOI] [PubMed] [Google Scholar]
- Burr D. H., Sugiyama H. Susceptibility to enteric botulinum colonization of antibiotic-treated adult mice. Infect Immun. 1982 Apr;36(1):103–106. doi: 10.1128/iai.36.1.103-106.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Dasgupta B. R., Sugiyama H. Molecular forms of neurotoxins in proteolytic Clostridium botulinum type B cultures. Infect Immun. 1976 Sep;14(3):680–686. doi: 10.1128/iai.14.3.680-686.1976. [DOI] [PMC free article] [PubMed] [Google Scholar]
- L'Hommedieu C., Stough R., Brown L., Kettrick R., Polin R. Potentiation of neuromuscular weakness in infant botulism by aminoglycosides. J Pediatr. 1979 Dec;95(6):1065–1070. doi: 10.1016/s0022-3476(79)80314-5. [DOI] [PubMed] [Google Scholar]
- Santos J. I., Swensen P., Glasgow L. A. Potentiation of Clostridium botulinum toxin aminoglycoside antibiotics: clinical and laboratory observations. Pediatrics. 1981 Jul;68(1):50–54. [PubMed] [Google Scholar]
- Sugiyama H. Clostridium botulinum neurotoxin. Microbiol Rev. 1980 Sep;44(3):419–448. doi: 10.1128/mr.44.3.419-448.1980. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Sugiyama H., Moberg L. J., Messer S. L. Improved procedure for crystallization of Clostridium botulinum type A toxic complexes. Appl Environ Microbiol. 1977 Apr;33(4):963–966. doi: 10.1128/aem.33.4.963-966.1977. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Vital Brazil O., Prado-Franceschi J. The nature of neuromuscular block produced by neomycin and gentamicin. Arch Int Pharmacodyn Ther. 1969 May;179(1):78–85. [PubMed] [Google Scholar]
- Wells C. L., Sugiyama H., Bland S. E. Resistance of mice with limited intestinal flora to enteric colonization by Clostridium botulinum. J Infect Dis. 1982 Dec;146(6):791–796. doi: 10.1093/infdis/146.6.791. [DOI] [PubMed] [Google Scholar]
- Wilson R., Morris J. G., Jr, Snyder J. D., Feldman R. A. Clinical characteristics of infant botulism in the United States: a study of the non-California cases. Pediatr Infect Dis. 1982 May-Jun;1(3):148–150. doi: 10.1097/00006454-198205000-00003. [DOI] [PubMed] [Google Scholar]